TD Cowen Maintains Market Perform on PTC Therapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joseph Thome maintains a Market Perform rating on PTC Therapeutics (NASDAQ:PTCT) and lowers the price target from $47 to $40.
May 24, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen analyst lowers PTC Therapeutics' price target from $47 to $40, maintaining a Market Perform rating.
The lowered price target from $47 to $40 by TD Cowen analyst Joseph Thome indicates a less optimistic outlook for PTC Therapeutics. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100